Biocon, Bristol-Myers in deal for oral insulin drug

MUMBAI Fri Nov 16, 2012 10:49am IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Biocon Ltd, India's top-listed biotechnology company, said it signed an agreement with Bristol-Myers Squibb Co under which the U.S. drugmaker will have the option to get the worldwide license to its oral insulin drug program.

Bristol Myers can choose to assume full responsibility for the development of the drug IN-105, if its mid-stage trial is successful.

Biocon, which has been looking to partner the drug for nearly two years, said it would receive a license fee as well as milestone payments and royalties based on commercial sales of the drug outside India. It will retain the rights to IN-105 in India.

Financial terms of the deal were not available.

Currently, there are no insulin tablets available and patients with diabetes who need insulin -- a naturally occurring protein that controls blood sugar -- must inject it.

Earlier this year, Pfizer scrapped a deal to sell injectable insulin products made by Biocon.

Biocon shares, which rose more than 4 percent in the previous session, were down 0.4 percent on Friday, while the broader market was up 0.3 percent.

(Reporting by Aradhana Aravindan; Editing by G.Ram Mohan)

FILED UNDER:

REUTERS EXCLUSIVE

Reuters Showcase

Documentary Banned

Documentary Banned

Documentary on 2012 Delhi gang rape banned in India.  Full Article 

RBI Rate Cut

RBI Rate Cut

RBI surprises with post-budget rate cut.  Full Article 

Beef Ban

Beef Ban

After beef ban, Hindu groups force abattoirs to close   Full Article 

Insurance Reforms

Insurance Reforms

Opposition support bolsters prospects for insurance reforms.  Full Article 

Axed by Censors

Axed by Censors

India's censor blocks 'Fifty Shades of Grey' from cinemas.  Full Article 

Bollywood Focus

Bollywood Focus

Franchise Man swoops in to save Bollywood.  Full Article 

Reuters Exclusive

Reuters Exclusive

India expects better monsoon rains this year.  Full Article 

Reuters Interview

Reuters Interview

Budget lacks wow, but good enough: Jim O’Neill.  Full Article 

Slim Chances

Slim Chances

Dozens of miners missing, feared dead after blast in east Ukraine.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage